Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL372248 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL372249 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL126073 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL5311584 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL372318 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL28984157 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL372317 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL126074 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL372405 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL23118547 | 0.97 | CA4 (0.80) | CA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119876923-B | Environment-friendly copper precipitation agent and preparation method and application thereof | 信丰正天伟电子科技有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119876923-A | Environment-friendly copper precipitation agent and preparation method and application thereof | 信丰正天伟电子科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119330414-A | High-entropy sulfide material for lithium ion battery cathode, and preparation method and application thereof | 江苏理工学院 | 2025-01-21 | — | — | CN | claimed |
| CN-117913272-A | Dekalium-sodium-embedded modified Prussian blue analogue, and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117865792-A | Preparation method of ferrous potassium citrate | 河南瑞贝佳生物科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-116632195-A | Molybdenum diselenide/carbon electrode material, preparation method thereof and normal/low temperature application | 上海大学 | 2023-08-22 | — | — | CN | claimed |
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2019-07-18 | — | — | US | claimed |
| US-20190160070-A1 | DRY BLEND FORMULATION OF TETRAHYDROBIOPTERIN | BIOMARIN PHARM INC (US) | 2019-05-30 | — | — | US | claimed |
| CN-109414442-A | (S) liquid preparation of-N- (5- ((R) -2- (2,5- difluorophenyl)-pyrrolidin-1-yl)-pyrazolo [1,5-A] pyrimidin-3-yl) -3- hydroxyl pyrrolidine -1- formamide | 洛克索肿瘤学股份有限公司 | 2019-03-01 | — | — | CN | claimed |
| EP-3439662-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | Loxo Oncology Inc. (US) | 2019-02-13 | — | — | EP | claimed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | SCHERING CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| CN-1635871-A | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2005-07-06 | — | — | CN | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1428525-A1 | Pharmaceutical preparations for the veterinary use containing acetylsalicylic acid in the form of buffered soluble powder | INDUSTRIA ITALIANA INTEGRATORI TREI S.P.A. (IT) | 2004-06-16 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
| WO-2001051600-A1 | DETERGENT TABLET | THE PROCTER & GAMBLE COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | CA4 4402/4885ALDH1A1 1446/4885CASP1 173/4885 |
| US-20190160070-A1 | DRY BLEND FORMULATION OF TETRAHYDROBIOPTERIN | QDPR, HTR1B, HTR3B | CA4 4694/4885ALDH1A1 4123/4885CASP1 3188/4885 |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | CA4 2466/4885ALDH1A1 3247/4885CASP1 2019/4885 |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | PMP22, TUBB2A, TUBB6 | CA4 678/4885ALDH1A1 1296/4885CASP1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.